● Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Condition: Breast Cancer · Sponsor: Celcuity Inc

PhasePhase 3

Planned participants1180

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Nadene Zack, MS · 844-310-3900 · viktoria-2_trial@celcuity.com

Always discuss trial participation with your own doctor first.

Locations (203)

City of Hope Medical Center	Duarte, California, United States	Not Yet Recruiting
Providence Medical Foundation	Fullerton, California, United States	Recruiting
UCLA Hematology Oncology Santa Monica	Los Angeles, California, United States	Recruiting
BRCR Medical Center, Inc- Internal Medicine	Plantation, Florida, United States	Recruiting
BRCR Medical Center, INC	Tamarac, Florida, United States	Recruiting
The University of Kansas Cancer Center	Westwood, Kansas, United States	Recruiting
Mercy Health-Paducah Cancer Center	Paducah, Kentucky, United States	Recruiting
American Oncology Partners, P.A.	Bethesda, Maryland, United States	Recruiting
Massachusetts General Hospital Cancer Center	Boston, Massachusetts, United States	Not Yet Recruiting
Henry Ford Health System	Detroit, Michigan, United States	Recruiting
Saint Luke's Cancer Institute	Kansas City, Missouri, United States	Recruiting
Washington University School of Medicine in Saint Louis	St Louis, Missouri, United States	Recruiting

+ 191 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06757634